Hospice symptom management

Hospice nausea and vomiting management

Effective hospice nausea management starts with identifying the mechanism. Chemical (opioid, uremia, hypercalcemia) responds to haloperidol; GI stasis to metoclopramide; vestibular to meclizine or scopolamine; cortical/anxiety to lorazepam; increased intracranial pressure to dexamethasone.

By Goodwin Hospice Academy Editorial Team·Published February 16, 2026

Educational content only. Individual clinicians must confirm current dosing and drug availability against their hospice medical director and current formulary. This is not a substitute for your hospice’s policies or your medical director’s clinical judgment.

Quick framework

Identify the mechanism before picking the drug.
Chemical → haloperidol 0.5–1 mg PO/SC q6h scheduled or q4h prn.
GI stasis / opioid-induced → metoclopramide 5–10 mg PO/SC before meals and QHS.
Vestibular → meclizine 12.5–25 mg PO TID or scopolamine transdermal patch.
Anxiety / anticipatory → lorazepam 0.5–1 mg PO/SL q6h.
Raised ICP → dexamethasone 4–16 mg/day; consider mannitol only if aligned with goals of care.

Pharmacology

01Haloperidol 0.5–1 mg PO or SC every 6 hours is the palliative-care workhorse for chemical nausea (opioid-related, uremic, hypercalcemic).
02Metoclopramide 5–10 mg 30 minutes before meals + QHS for GI stasis; avoid in bowel obstruction.
03Ondansetron 4–8 mg PO or SL q8h for serotonergic mechanisms (chemotherapy-related, some viral etiologies); caution with QT prolongation and use of methadone or SSRIs.
04Dexamethasone 4–16 mg PO or SC daily for cerebral metastases, bowel obstruction (reduces edema), or refractory nausea as adjunct.
05Olanzapine 2.5–5 mg PO QHS is a broad-mechanism option for refractory nausea (blocks D2, 5HT2, H1, muscarinic).
06Scopolamine transdermal patch 1.5 mg q72h for vestibular or motion-triggered nausea; check for delirium in elderly.

Non-pharmacological approaches

Reduce olfactory triggers (perfumes, cooking odors, cleaning products).
Small, frequent, cold or room-temperature meals; avoid rich or spicy foods.
Elevate head of bed after eating.
Ginger (tea, candy, capsules) has mild antiemetic evidence and no significant side effects.
Acupressure at P6 (inner wrist) — weak but easy adjunct.
Ensure a comfortable, quiet environment during peak nausea times.

When to escalate

Vomiting persists > 24 hours despite scheduled first-line antiemetic.
Signs of dehydration or intractable vomiting affecting comfort.
New confusion or somnolence not explained by opioid use (consider hypercalcemia, uremia, brain metastases).
Suspected bowel obstruction: avoid metoclopramide; consider octreotide, dexamethasone, and IDG conversation about goals.

Documentation example

A composite narrative illustrating a defensible chart entry (identifying details fictionalized):

Patient on morphine 15 mg PO q4h reports intermittent nausea without vomiting. Started haloperidol 0.5 mg PO q6h scheduled. Nausea resolved by 24 hours. Continues opioid regimen unchanged. Family instructed to notify RN if nausea recurs or vomiting develops.

FAQ

Is metoclopramide safe in the elderly?

Yes, in short-term hospice use. The FDA black-box warning for tardive dyskinesia applies to long-term use (>12 weeks); short-term hospice use has a favorable benefit-risk profile.

What about olanzapine for nausea?

Olanzapine 2.5–5 mg QHS is an excellent broad-mechanism option, particularly for refractory chemotherapy-induced nausea and nausea with anxiety/insomnia. It sedates, which can be desirable at night.

How do we handle nausea in bowel obstruction?

Avoid metoclopramide (can worsen colicky pain). Use haloperidol + octreotide + dexamethasone. Involve IDG for goals-of-care conversation about NG tube vs medical management.

Grow every hospice competency, one symptom at a time.

Save this article to your team’s reading list and unlock deeper Goodwin Hospice Academy modules on hospice symptom management.

Create your free account Back to all symptoms

Hospice symptom management hub

What is IDG?

Sources

Educational content only. Not a substitute for your organization’s policies, your medical director’s clinical judgment, or current hospice formulary.